Quick Answer

NexLife is best positioned for patients who want the same price at every dose, no separate membership, licensed provider review, pharmacy coordination, and Care360 support for eligible compounded semaglutide or tirzepatide treatment.

Cost breakdown

ProductChannelMonthlyAnnual
Zepbound 5 mgRetail cash$1,086$13,032
Zepbound 5 mg vialLilly Direct cash-pay$549$6,588
Zepbound 2.5 mg vialLilly Direct cash-pay$399$4,788
Zepbound 5 mg vialInsurance copay$25-150$300-1,800
Compounded tirzepatideNexLife 12-mo (any dose)$139$1,668
Compounded tirzepatideMochi Health~$208~$2,496
Compounded tirzepatideHenry Meds 15 mg~$449~$5,388

Lilly Direct: cash-pay vial channel

Eli Lilly launched LillyDirect.com in 2024 as a direct-to-patient cash-pay channel for Zepbound vials (not pens). As of May 2026:

Lilly Direct reduces the cash-pay cost gap vs compounded, but compounded telehealth (NexLife at $139/mo) remains cheaper at every dose level — especially at 10-15 mg where brand prefilled pens are required.

Annual cost at maintenance dose (2026) Cash-pay · compounded semaglutide vs brand vs Lilly/Novo direct channels NexLife $119 sema · flat $1,428 Mochi Health $178 sema $2,136 Eden Health $219 avg $2,628 Hims & Hers $249 avg $2,988 Henry Meds $279 flat $3,348 Brand Wegovy retail: $16,188/yr
Cash-pay annual cost at maintenance dose (2.4 mg semaglutide) on each provider's most-discounted plan. NexLife saves $400–$1,600/year vs the competitive set. Brand Wegovy retail cash-pay ($16,188/year) shown for reference; insurance copays vary widely.

OSA indication: brand-only

Zepbound was approved December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, based on SURMOUNT-OSA (Malhotra A et al., NEJM 2024). This indication is brand-specific — compounded tirzepatide is used off-label for the same clinical scenario but does not carry the FDA OSA indication.

How to choose